𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus

✍ Scribed by J.V. Williams; J.G. Marks JR.; E.M. Billingsley

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
322 KB
Volume
142
Category
Article
ISSN
0007-0963

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Paraneoplastic pemphigus (PNP) is a rare autoimmune blistering disease with circulating antibodies that bind the cell surface of the epidermis and other non-stratifying epithelia, and immunoprecipitate a complex of four or five proteins (250 kDa, 230 kDa, 210 kDa, 190 kDa and occasionally 170 kDa). 1, 2 Combinations of immunosuppressive agents are usually required to obtain even partial control of the skin lesions. 3 Mucous membrane lesions are refractory to treatment. We describe a patient with PNP whose skin and oral lesions are quiescent following treatment with oral mycophenolate mofetil.

πŸ“œ SIMILAR VOLUMES

Mycophenolate mofetil for remission main
Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis
✍ Langford, Carol A. ;Talar-Williams, Cheryl ;Sneller, Michael C. πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 2 views

## Objective: To examine the safety of mycophenolate mofetil (mmf) for remission maintenance in patients with wegener's granulomatosis (wg) who had been treated with daily cyclophosphamide (cyc) and glucocorticoids to induce remission. ## Methods: Fourteen patients were treated for active wg usin

Successful treatment of paraneoplastic p
Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL
✍ M. Heizmann; P. Itin; M. Wernli; L. Borradori; M.J. Bargetzi πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 72 KB πŸ‘ 2 views

Paraneoplastic pemphigus is a severe mucocutaneous disease associated in most cases with B-cell lymphoproliferative disorders. Independent of the course of the underlying malignancy, this autoimmune skin disease is resistant to any treatment in most cases and may lead to death by infectious complica

Change of treatment from cyclosporin to
Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis
✍ S.C. Davison; R. Morris-Jones; A.V. Powles; L. Fry πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 192 KB

Eight patients whose severe psoriasis was treated with long-term cyclosporin (range 2-11 years; mean 7.6 years) were changed to mycophenolate mofetil (MMF), because of nephrotoxicity in seven and hypertension and lack of efficacy in one. In five patients psoriasis control significantly deteriorated

The role of mycophenolate mofetil in cli
The role of mycophenolate mofetil in clinical renal transplantation
✍ E. E. Hodge πŸ“‚ Article πŸ“… 1996 πŸ› Springer-Verlag 🌐 English βš– 793 KB

Mycophenolate mofetil (MM) is the ester derivative of mycophenolic acid (MPA), which exerts immunosuppressive activity by inhibiting de novo purine biosynthesis. Following animal models and pilot studies in human renal allograft recipients that confirmed MM's ability to prevent and half rejection ep

Mycophenolate mofetil in the therapy of
Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome
✍ C. Schneider; R. Gold; M. SchΓ€fers; K.V. Toyka πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 162 KB

## Abstract Mycophenolate mofetil 1.5 g daily (30 mg/kg body weight) was given to a patient with ankylosing spondylitis, ulcerative colitis, and severe refractory polymyositis after conventional treatment regimes had failed. No severe side effects occurred. Considerable improvement of clinical symp